Technical Analysis for RANI - Rani Therapeutics Holdings, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | -0.98% | |
| Lower Bollinger Band Walk | Weakness | -0.98% | |
| Lower Bollinger Band Touch | Weakness | -0.98% | |
| Oversold Stochastic | Weakness | -0.98% | |
| NR7 | Range Contraction | -1.22% | |
| Narrow Range Bar | Range Contraction | -1.22% | |
| Lower Bollinger Band Walk | Weakness | -1.22% | |
| BB Squeeze Ended | Range Expansion | -1.22% | |
| Below Lower BB | Weakness | -1.22% | |
| Oversold Stochastic | Weakness | -1.22% |
| Alert | Time |
|---|---|
| Possible Inside Day | 1 minute ago |
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Down 1% | about 3 hours ago |
| Up 1% | about 4 hours ago |
| Lower Bollinger Band Support | about 4 hours ago |
Get a Trading Assistant
- Earnings date: 11/08/2024
Rani Therapeutics Holdings, Inc. Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Diabetes Endocrine System Osteoporosis Peptide Hormones Growth Hormone Psoriatic Arthritis Glands Glucagon Growth Hormone Deficiency Neuroendocrine Tumors Acromegaly Hypoparathyroidism Neuroendocrinology Parathyroid Hormone
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.75 |
| 52 Week Low | 1.903 |
| Average Volume | 2,132,896 |
| 200-Day Moving Average | 3.61 |
| 50-Day Moving Average | 2.34 |
| 20-Day Moving Average | 2.35 |
| 10-Day Moving Average | 2.34 |
| Average True Range | 0.21 |
| RSI (14) | 39.02 |
| ADX | 18.08 |
| +DI | 15.28 |
| -DI | 23.18 |
| Chandelier Exit (Long, 3 ATRs) | 2.04 |
| Chandelier Exit (Short, 3 ATRs) | 2.63 |
| Upper Bollinger Bands | 2.66 |
| Lower Bollinger Band | 2.04 |
| Percent B (%b) | 0.02 |
| BandWidth | 26.23 |
| MACD Line | -0.07 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0468 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.20 | ||||
| Resistance 3 (R3) | 2.20 | 2.15 | 2.17 | ||
| Resistance 2 (R2) | 2.15 | 2.11 | 2.15 | 2.16 | |
| Resistance 1 (R1) | 2.10 | 2.09 | 2.08 | 2.10 | 2.16 |
| Pivot Point | 2.05 | 2.05 | 2.04 | 2.05 | 2.05 |
| Support 1 (S1) | 2.00 | 2.01 | 1.98 | 2.00 | 1.94 |
| Support 2 (S2) | 1.95 | 1.99 | 1.95 | 1.94 | |
| Support 3 (S3) | 1.90 | 1.95 | 1.93 | ||
| Support 4 (S4) | 1.90 |
